Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. - Test2 - elhamkhani - TriplyDB

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

http://www.wikidata.org/entity/Q27863396

about

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Strategies for early detection of resectable pancreatic cancer Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review Neoadjuvant therapy for pancreas cancer: past lessons and future therapies Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pancreatic cancer treatment and research: an international expert panel discussion.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Biomarkers in pancreatic adenocarcinoma: current perspectives Genetic factors affecting patient responses to pancreatic cancer treatment FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer New challenges in perioperative management of pancreatic cancer Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.Fluoropyrimidine Activity Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.Equilibrative nucleoside transporters-A review.Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.Evolution of systemic therapy for advanced pancreatic cancer.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.Understanding Drug Resistance in Breast Cancer with Mathematical Oncology Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma Personalising pancreas cancer treatment: When tissue is the issue.Pancreatic cancer-improved care achievable Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Therapeutic options for the management of pancreatic cancer.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.Pancreatic cancer genomics: where can the science take us?S-1 in the treatment of pancreatic cancer.

P2860

Q24273350-5FDD65CD-C8FF-4BB5-ACF6-7EA948B3499E Q24564006-9D67C014-C51F-4F66-94D8-4C01668B0EA4 Q26746031-F05033C6-533C-4EA3-B830-C2D543472A12 Q26752368-0493F17B-F56E-4C72-875C-89B0A19CF4C1 Q26767120-9CBD1401-514B-4C8F-BAA9-AD6AB99062FC Q26801411-BC6A1B69-2561-4079-83D0-D7BB8C339EA7 Q26862139-C577F3B4-160A-447B-B91E-95942FBB8974 Q27004292-D2FACEBD-0519-4436-B087-F54D69879F2D Q27021716-2789083C-5E6A-4503-A1AC-5A7AAC330BBF Q27690868-E0A404B9-248D-40E8-970D-C1C1703DE911 Q28066268-40B2392D-5842-44D4-8ECD-B02715AABF1F Q28072309-0942BF05-D747-45CE-A519-0C23B2265ED6 Q28075293-A31D21BD-2A03-4CD0-B8AE-B20CDDFD1C48 Q28075540-81496B90-3D4B-4C2C-B0C3-A6BD38B66E23 Q28082422-F23F6134-AFBA-410E-814F-166DB0535787 Q28486221-554ADED4-7833-4CD9-80E6-DDBD313CF9BF Q29883401-DA47C042-FA92-4A93-9CCC-1FB2AB43D323 Q30238470-7F6E1BD1-A0E0-4F18-AFB6-41C4DAA3887A Q30244329-9C5194F7-CBE0-4C47-8D78-FE35DBFE3AD4 Q30405605-6AD49BCD-96AA-4E4F-A101-C5286609348E Q33418045-C85F7895-AA4E-409B-991C-075F83A24244 Q33557413-EE595E2E-3C89-4C6B-A59C-AF9CBC5BF48E Q33575608-CC64EF07-CD02-4B20-8E86-DD45C81B18F4 Q33630872-2E4AB3AA-9448-4EDD-9A74-63B08376BB50 Q33690336-ECCE00BF-6F17-4259-9DA0-4AF9258B8A4A Q33711106-1EFC43B7-0203-4B10-AED0-15B778DF3043 Q33727842-2FD32071-E852-41C2-A97F-9E6157C97CA2 Q33751227-84439D4C-C479-4B5C-986A-5DBACA25C53D Q33801384-AF2FACB3-5C4B-4808-812E-FCCD338A0EA9 Q34036659-5151CD6C-845D-4CB3-85A2-FE3E50F374A9 Q34067863-8F4B443F-1223-4FED-BDC5-A471C7486005 Q34093776-DA97DD92-A197-4288-BE5C-37B6DFD40AE9 Q34127857-DF20B21F-5AAB-4F97-9A72-CE0A08C0FFE8 Q34177223-17AFA35B-45A1-4490-91D1-305379BFD118 Q34234101-A5B100D4-0021-4251-B86A-7497F8A1D0B9 Q34254837-4C342A31-6ED0-4237-B973-56994C23DCEA Q34283650-768D0078-116E-4ED0-B80D-B71F4C705D18 Q34334926-E9705071-829B-40CC-8F85-9D2F1F984564 Q34447458-B01AF7B4-6ACA-43C0-9F66-DCDE1882C0C3 Q34467156-8F5CAFAB-FFC9-4552-8662-FC4E34FC9D34

P2860

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

http://www.wikidata.org/entity/Q27863396

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@ast

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@en

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@nl

type

label

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@ast

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@en

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@nl

altLabel

Human equilibrative nucleoside ...... atients with pancreatic cancer

@en

prefLabel

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@ast

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@en

Human equilibrative nucleoside ...... tients with pancreatic cancer.

@nl

P1433

Q27863396-1E20F5D0-41DA-4127-B40B-643E6524155E

P1476

Q27863396-ECCE22E3-FAAF-474F-9584-115F1E69929D

P2093

Q27863396-04FD1C8A-32BB-4F3B-A899-A086C915BAC4

Q27863396-12B3D0DD-C8AF-435A-8792-3C9279A5D483

Q27863396-1CD34F3E-154D-49F6-A276-4A44B28E32E5

Q27863396-5ED5D3A9-2C80-4FD1-9332-65A6996FFA0F

Q27863396-73D0E340-809E-4B20-81FB-444786574F40

Q27863396-7DA7CD8C-F849-44C7-BEFB-7A6007826184

Q27863396-92763FCA-49AF-4962-AA92-D7137250193F

Q27863396-9BD7A283-16DB-4F4B-90F5-1E33418CC2AF

Q27863396-B18E4346-F878-42A3-8164-CD73332DE432

Q27863396-EEDBA401-3B34-40FA-BABD-4BB69A9ACEDE

P304

Q27863396-F4EECBAF-B295-4432-B715-F50EE809F85E

P31

Q27863396-D5CF17C8-EAF4-4A84-B2EC-AC64AADC3D6F

P3181

Q27863396-0F8D104F-9AD2-4474-9D52-D56F371B2158

P356

Q27863396-F909EC0A-4B69-4FD4-803E-B672621337CF

P407

Q27863396-ACA6DDAF-F50A-44E5-8002-C5D2D032F6C7

P433

Q27863396-26F59FF9-777F-4012-A5E1-BE2E789F6058

P478

Q27863396-F15061A4-3BD2-4FF6-88A3-312553DF247C

P50

Q27863396-3798CAC4-BD60-4677-B817-B6002AC1CBF9

Q27863396-5313D3DA-CEDF-4473-9ED9-8A383860A7BE

P577

Q27863396-9C48BB92-5245-4377-A961-DF675FBDDE28

P698

Q27863396-C783BBB3-51BA-4FEB-80B8-B70F9361EF0E

P921

Q27863396-788B1306-2707-4748-8018-476BFF2E7BED

P3181

P356

J.GASTRO.2008.09.067

P1433

Gastroenterology

P1476

Human equilibrative nucleoside ...... atients with pancreatic cancer

@en

P2093

A Bowen Benson

http://www.w3.org/2001/XMLSchema#string

Ali Ammar

http://www.w3.org/2001/XMLSchema#string

Carol E Cass

http://www.w3.org/2001/XMLSchema#string

Hany Elsaleh

http://www.w3.org/2001/XMLSchema#string

James J Farrell

http://www.w3.org/2001/XMLSchema#string

John Macdonald

http://www.w3.org/2001/XMLSchema#string

Miguel Garcia

http://www.w3.org/2001/XMLSchema#string

Raymond Lai

http://www.w3.org/2001/XMLSchema#string

Ross Abrams

http://www.w3.org/2001/XMLSchema#string

William F Regine

http://www.w3.org/2001/XMLSchema#string

P304

187-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

798351

http://www.w3.org/2001/XMLSchema#string

P356

10.1053/J.GASTRO.2008.09.067

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18992248

http://www.w3.org/2001/XMLSchema#string

P921